Wedbush reiterated their outperform rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report ...

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) had its price objective upped by equities researchers at HC Wainwright from $10.00 to $24.00 in a research report issued on Friday,Benzinga reports ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

Oncology-focused biopharma Compass Therapeutics (NASDAQ:CMPX) announced Tuesday that tovecimig (CTX-009), its treatment for ...

In trading on Thursday, shares of Compass Diversified's 7.875% Series C Cumulative Preferred Shares (Symbol: CODI.PRC) were yielding above the 9% mark based on its quarterly dividend (annualized ...

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel ...

one can better assess the future performance of a company If you want to know who really controls Compass Therapeutics, Inc. (NASDAQ:CMPX), then you'll have to look at the makeup of its share ...

LONDON & NEW YORK, March 11, 2025--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...